Last reviewed · How we verify
Control group: Oxiracetam Injection
Oxiracetam enhances neuronal membrane fluidity and increases oxygen utilization in the brain, promoting cognitive function and neuroprotection.
Oxiracetam enhances neuronal membrane fluidity and increases oxygen utilization in the brain, promoting cognitive function and neuroprotection. Used for Cognitive decline and memory impairment, Stroke recovery and post-stroke cognitive dysfunction, Age-related cognitive disorders.
At a glance
| Generic name | Control group: Oxiracetam Injection |
|---|---|
| Sponsor | Nanjing Yoko Biomedical Co., Ltd. |
| Drug class | Nootropic agent |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Oxiracetam is a cyclic derivative of GABA that modulates neuronal membrane properties and increases cerebral blood flow and oxygen consumption. It enhances synaptic plasticity and neurotransmitter synthesis, particularly acetylcholine, supporting cognitive processes. The drug is believed to stabilize cell membranes and improve mitochondrial function in neurons.
Approved indications
- Cognitive decline and memory impairment
- Stroke recovery and post-stroke cognitive dysfunction
- Age-related cognitive disorders
Common side effects
- Insomnia
- Nervousness or agitation
- Headache
- Gastrointestinal disturbances
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: